Therapy of autoimmune bullous diseases

نویسنده

  • Diya F Mutasim
چکیده

Autoimmune bullous diseases result from an immune response to molecular components of the desmosome or basement membrane. Bullous diseases are associated with a high degree of morbidity and occasional mortality. Therapy of bullous diseases consists of suppressing the immune system, controlling inflammation and improving healing of erosions. The therapeutic agents used in the treatment of bullous diseases may be associated with high morbidity and occasional mortality. Successful treatment requires understanding of the pathophysiology of the disease process and the pharmacology of the drugs being used.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Association between HLA-DQB1*03:01 and Bullous Pemphigoid in Iranian Patients

Background: A common Human Leukocyte Antigen (HLA) class II allele, DQβ1*03:01, seems to be associated with Bullous pemphigoid (BP) in Caucasians whereas previous studies in other ethnic groups showed other HLA class II alleles as genetic predisposing factors for BP. Objective: To investigate the association of HLA class II alleles and haplotypes with BP in Iranian population. Methods: Fifty pa...

متن کامل

Immunofluorescence Pattern of Autoimmune Bullous Diseases in Iranian Patients

Background & Objective: Autoimmune bullous diseases are associated with autoimmunity against structural components in the skin and mucous membranes. Autoantibodies are against the intercellular junctions in pemphigus disease and hemidesmosomal unchoring complex in pemphigiod diseases and epidermolysis bullosa aquisita. The tissue-bound and circulating serum autoantibodies can be detect...

متن کامل

A cross-sectional study of clinical, histopathological and direct immmunofluorescence diagnosis in autoimmune bullous diseases

Background: Immunobullous diseases are morphologically heterogeneous and the differentiation between various subtypes is essential for proper treatment and prognosis. The aim of our study was to analyze and correlate clinical, histopathological, and immunofluorescence findings in autoimmune bullous diseases.Method: A c...

متن کامل

Is there any association between a vitamin D receptor gene polymorphism (FokI) and pemphigus vulgaris?

Background: Pemphigus vulgaris (PV) is an autoimmune bullous disease of the skin and mucous membranes caused by activation and proliferation of T cells, production of Th2 cytokine profile and pathogenic antibodies. Vitamin D is a probable immunodeviator to Th2, which its actions are mediated through the vitamin D receptor (VDR). FokI is the only single nucleot...

متن کامل

Adverse reactions associated with intravenous immunoglobulin therapy in patients with dermatologic diseases: An 11-year retrospective study

Background: Intravenous immunoglobulin (IVIG) is used to treat many autoimmune and immunodeficiency disorders. The main indications of IVIG in dermatology include treatment for resistant autoimmune bullous diseases, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Although generally welltolerated, various adverse effects can occur.Methods: We designed a retrospective study ...

متن کامل

Serum protein carbonyl and total antioxidant capacity levels in pemphigus vulgaris and bullous pemphigoid

Background: Pemphigus diseases including pemphigus vulgaris (PV) and bullous pemphigoid (BP) are autoimmune diseases that cause severe blistering of the skin and mucous membranes. Among inflammatory mediators, reactive oxygen species (ROS) are involved in the pathogenesis of a wide variety of diseases through oxidative stress for which protein carbonyl (PC) and total antioxidant capacity (TAC) ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Therapeutics and Clinical Risk Management

دوره 3  شماره 

صفحات  -

تاریخ انتشار 2007